

Provider Network News

RSV Monoclonal Antibody Nirsevimab is a Benefit of Texas Medicaid and CHIP

Key Details

Effective October 2, 2023, respiratory syncytial virus (RSV) monoclonal antibody nirsevimab (procedure codes 90380 and 90381) and its administration are benefits of Texas Medicaid and CHIP for individuals who are birth through 19 months of age.

Administration of nirsevimab on dates of service October 2, 2023, through October 5, 2023, may be reimbursed using existing procedure code 96372.

Effective October 6, 2023, nirsevimab administration procedure codes 96380 and 96381 may be reimbursed for the following Medicaid provider types and places of service:

Place of Service	Provider Type
Office	<ul style="list-style-type: none"> Physician Physician Assistant Nurse Practitioner Clinical Nurse Specialist Certified Nurse Midwife Licensed Midwife Comprehensive Care Program (CCP) Texas Health Steps Medical Provider
Outpatient Hospital	<ul style="list-style-type: none"> Hospital Providers, Texas Health Steps Medical Providers
Birthing Center	<ul style="list-style-type: none"> Physician Physician Assistant Nurse Practitioner Clinical Nurse Specialist Certified Nurse Midwife Licensed Midwife Birthing Center Texas Health Steps Medical Provider

Limitations for Medicaid Coverage

Procedure codes 96380 and 96381 are limited to two services per lifetime and should never be billed together. They must be billed with either procedure code 90380 or 90381.

The administration of intramuscular palivizumab (Synagis) may be denied if it is billed after the administration of nirsevimab.

CHIP Coverage

Effective October 6, 2023, nirsevimab administration procedure codes 96380 and 96381 are covered by CHIP under clinic services, physician/physician extender professional services, outpatient services, and services rendered by a certified midwife or physician in a licensed birthing center.

Other Considerations

Vaccines and related products that are administered to individuals who are eligible for the Vaccines for Children (VFC) program should come from VFC-provided stocks. Claims for nirsevimab that are submitted for reimbursement will process as informational only when administered to individuals who are birth through 19 months of age.

Reprocessing

PCHP will update our system and reprocess affected claims submitted with these procedure codes and date of service on or after October 2, 2023. Providers are not required to appeal the claims unless they are denied for additional reasons after the claims reprocessing is complete. Providers may bill PCHP retroactively for nirsevimab procedure codes and related administration procedure codes.